Declarative memory deficits and schizophrenia: Problems and prospects

Neurobiology of Learning and Memory

Volumn 96, Issue 4, 2011, Pages 544-552

  Stone, William S ^a   Hsi, Xiaolu ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Animal models; Cognitive deficits; Declarative memory; Diabetes; Genetics; Hippocampus; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

COMORBIDITY; DECLARATIVE MEMORY; DIABETES MELLITUS; DISEASE MODEL; EXPERIMENTAL ANIMAL; GLUCOSE METABOLISM; HIPPOCAMPUS; HUMAN; INSULIN SENSITIVITY; MEMORY DISORDER; NONHUMAN; RELATIVE; REVIEW; SCHIZOPHRENIA;

HIPPOCAMPUS; HUMANS; MEMORY; MEMORY DISORDERS; NEUROPSYCHOLOGICAL TESTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 82355186732     PISSN: 10747427     EISSN: 10959564     Source Type: Journal    
DOI: 10.1016/j.nlm.2011.04.006     Document Type: Review

References (171)

1. Achim A.M., Lepage M. Episodic memory-related activation in schizophrenia: Meta-analysis. British Journal of Psychiatry 2005, 187:500-509.
2. Adler L.E., Olincy A., Waldo M., Harris J.G., Griffith J., Stevens K., et al. Schizophrenia, sensory gating, and nicotinic receptors. Schizophrenia Bulletin 1998, 24:189-202.
3. Aleman A., Hijman R., de Haan E.H., Kahn R.S. Memory impairment in schizophrenia: A meta-analysis. American Journal of Psychiatry 1999, 156:1358-1366.
4. Amann L.C., Gandal M.J., Halene T.B., Ehrichman R.S., White S.L., McCarren H.S., et al. Mouse behavioral endophenotypes for schizophrenia. Brain Research Bulletin 2010, 83:147-161.
5. Austin C.P., Ky B., Ma L., Morris J.A., Shughrue P.J. Expression of dirupted-in-schizophrenia-1, a schizophrenia-associated gene, is prominent in the mouse hippocampus throughout development. Neuroscience 2004, 124:3-10.
6. Ayhan Y., Sawa A., Ross C.A., Pletnikov M.V. Animal models of gene-environment interactions in schizophrenia. Behavioral Brain Research 2009, 204:274-281.
7. Babovic D., O'Tuathaigh C.M.P., O'Connor A.M., O'Sullivan G.J., Tighe O., Croke D.T., et al. Phenotypic characterization of cognition and social behavior in mice with heterozygous versus homozygous deletion of catechol-O-transferase. Neuroscience 2008, 155:1021-1029.
8. Barrett S.L., Mulholland C.C., Cooper S.J., Rushe T.M. Patterns of neurocognitive impairment in first-episode bipolar disorder and schizophrenia. British Journal of Psychiatry 2009, 195:67-72.
9. Benes F.M., Kwok E.W., Vincent S.L., Todtenkopf M.S. A reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives. Biological Psychiatry 1998, 44:88-97.
10. Bogerts B. The temporolimbic system theory of positive schizophrenic symptoms. Schizophrenia Bulletin 1997, 23:423-435.
11. Boos H.B.M., Aleman A., Cahn W., Pol H.H., Kahn R.S. Brain volumes in relatives of patients with schizophrenia: A meta-analysis. Archives of General Psychiatry 2007, 64:297-304.
12. Bouchard T.J. Genetic and environmental influences on adult intelligence and special mental abilities. Human Biology 1998, 70:257-279.
13. Brambilla P., Harenski K., Nocoletti M., Sassi R.B., Mallinger A.G., Kupfer F.E., et al. MRI investigation of temporal lobe structures in bipolar patients. Journal of Psychiatric Research 2003, 37:287-295.
14. Broadbent N.J., Clark R.E., Zola S., Squire L.R. The medial temporal lobe and memory. Neuropsychology of memory 2002, 3-23. The Guilford Press, New York. L.R. Squire, D.L. Schacter (Eds.).
15. Brown S., Inskip H., Barraclough B. Causes of the excess mortality of schizophrenia. British Journal of Psychiatry 2000, 177:212-217.
16. Brzoka M.M., Radyushkin K., Wichert S.P., Ehrenreich H., Rossner M.J. Cognitive and sensorimotor gating impairments in transgenic mice overexpressing the schizophrenia susceptibility gene Tcf4 in the brain. Biological Psychiatry 2010, 68:33-40.
17. Calkins M.E., Tepper P., Gur R.C., Ragland J.D., Klei L., Wiener H.W., et al. Project among African-Americans to explore risks for schizophrenia (PAARTNERS): Evidence for impairment and heritability of neurocognitive functioning in families of schizophrenia patients. American Journal of Psychiatry 2010, 167:459-472.
18. Cannon T.D., Zorrilla L.E., Shtasel D., Gur R.E., Gur R.C., Marco E.J., et al. Neuropsychological functioning in siblings discordant for schizophrenia and healthy volunteers. Archives of General Psychiatry 1994, 51:651-661.
19. Cervos-Navarro J., Kater S.B. Selective vulnerability in brain hypoxia. Critical Review of Neurobiology 1991, 6:149-182.
20. Cirillo M.A., Seidman L.J. Verbal declarative memory dysfunction in schizophrenia: From clinical assessment to genetics and brain mechanisms. Neuropsychology Review 2003, 13:43-77.
21. Convit A. Links between cognitive impairment in insulin resistance: An explanatory model. Neurobiology of Aging 2005, 26S:S31-S35.
22. Convit A., Wolf O.T., Tarshish C., de Leon M.J. Reduced glucose tolerance is associated with poor memory performance and hippocampal atrophy among normal elderly. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:2019-2022.
23. Coyle J. The glutamatergic dysfunction hypothesis for schizophrenia. Harvard Review of Psychiatry 1996, 3:241-253.
24. Dasgupta A., Singh O.P., Rout J.K., Saha T., Mandal S. Insulin resistance and metabolic profile in antipsychotic naive schizophrenia patients. Progress in Neuropsychopharmacology and Biological Psychiatry 2010, 34:1202-1207.
25. Davila E.P., Florez H., Fleming L.E., Lee D.J., Goodman E., Leblanc W.G., et al. Prevalence of the metabolic syndrome among US workers. Diabetes Care 2010, (Epub ahead of print).
26. Desbonnet L., Waddington J.L., Tuathaigh C.M. Mice mutant for genes associated with schizophrenia: Common phenotype or distinct endophenotypes?. Behavioral Brain Research 2009, 204:258-273.
27. Dickinson D., Gold J.M., Dickerson F.B., Medoff D., Dixon L.B. Evidence of exacerbated cognitive deficits in schizophrenia patients with comorbid diabetes. Psychosomatics 2008, 49:123-131.
28. Eack S.M., Greenwald D.P., Hogarty S.S., Cooley S.J., DiBarry A.L., Montrose D.M., et al. Cognitive enhancement therapy for early-course schizophrenia: Effects of a two-year randomized controlled trial. Psychiatric Services 2009, 60:1468-1476.
29. Eastwood S.L., Harrison P.J. Decreased expression of vesicular glutamate transporter 1 and complexin II mRNAs in schizophrenia: Further evidence for a synaptic pathology affecting glutamate neurons. Schizophrenia Research 2005, 73:159-172.
30. Ebner F., Tepest R., Dani I., Pfeiffer U., Schulze T.G., Rietschel M., et al. The hippocampus in families with schizophrenia in relation to obstetric complications. Schizophrenia Research 2008, 104:71-78.
31. Egan M.F., Goldberg T.E., Kolachana B.S., Callicott J.H., Mazzanti C.M., Straub R.E., et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:6917-6922.
32. Eichenbaum H. Declarative memory: Insights from cognitive neurobiology. Annual Review of Psychology 1997, 48:547-572.
33. Eichenbaum H. Memory representations in the parahippocampal region. The parahippocampal region: Organization and role in cognitive function 2002, 165-184. Oxford University Press, New York. M. Witter, F. Wouterlood (Eds.).
34. Fagiolini A., Goracci A. The effects of undertreated chronic medical illnesses in patients with severe mental disorders. Journal of Clinical Psychiatry 2009, 70(Suppl. 3):22-29.
35. Faraone S.V., Seidman L.J., Kremen W.S., Pepple J.R., Lyons M.J., Tsuang M.T. Neuropsychological functioning among the nonpsychotic relatives of schizophrenic patients: A diagnostic efficiency analysis. Journal of Abnormal Psychology 1995, 104:286-304.
36. Faraone S.V., Seidman L.J., Kremen W.S., Toomey R., Pepple J.R., Tsuang M.T. Neuropsychological functioning among the nonpsychotic relatives of schizophrenic patients: A four-year follow-up study. Journal of Abnormal Psychology 1999, 108:176-181.
37. Faraone S.V., Seidman L.J., Kremen W.S., Toomey R., Pepple J.R., Tsuang M.T. Neuropsychological functioning among the nonpsychotic relatives of schizophrenic patients: The effect of genetic loading. Biological Psychiatry 2000, 48:120-126.
38. Fernandez-Egea E., Bernardo M., Parellada E., Justicia A., Garcia-Rizo C., Esmatjes E., et al. Glucose abnormalities in the siblings of people with schizophrenia. Schizophrenia Research 2008, 103:110-113.
39. Finkel D., Pedersen N., McGue M. Genetic influences on memory performance in adulthood: Comparison of Minnesota and Swedish twin data. Psychology and Aging 1995, 10:437-446.
40. Fleischhacker W.W., Cetkovich-Bakmas M., De Hert M., Hennekens C.H., Lambert M., Leucht S., et al. Comorbid somatic illnesses in patients with severe mental disorders: Clinical, policy and research challenges. Journal of Clinical Psychiatry 2008, 69:514-519.
41. Ford E.S., Giles W.H. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care 2003, 26:575-581.
42. Ghose S., Chin R., Gallegos A., Roberts R., Coyle J.T., Tamminga C.A. Localization of NAAG-related gene expression deficits to the anterior hippocampus in schizophrenia. Schizophrenia Research 2009, 111:131-137.
43. Gilvarry C.M., Sham P.C., Jones P.G., Cannon M., Wright P., Lewis S.W., et al. Family history of autoimmune diseases in psychosis. Schizophrenia Research 1996, 19:33-40.
44. Gold P.E. Role of glucose in regulating the brain and cognition. American Journal of Clinical Nutrition 1995, 61(supplement):987S-995S.
45. Gold J.M. Cognitive deficits as treatment targets in schizophrenia. Schizophrenia Research 2004, 72:21-28.
46. Gold J.M., Blaxton T.A., Hermann B.P., Randolph C., Fedio P., Goldberg T.E., et al. Memory and intelligence in lateralized temporal lobe epilepsy and schizophrenia. Schizophrenia Research 1995, 17:59-65.
47. Gold S.M., Dziobek I., Sweat V., Tirsi A., Rogers K., Bruehl H., et al. Hippocampal damage and memory impairments as possible early brain complications of type 2 diabetes. Diabetologia 2007, 50:711-719.
48. Goldberg T.E., Goldman R.S., Burdick K.E., Malhotra A.K., Lencz T., Patel R.C., et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: Is it a practice effect?. Archives of General Psychiatry 2007, 64:1115-1122.
49. Gottesman I.I., Gould T.D. The endophenotype concept in psychiatry: Etymology and strategic intentions. American Journal of Psychiatry 2003, 160:636-645.
50. Gottesman I.I., Hanson D.R. Human development: Biological and genetic processes. Annual Review of Psychology 2005, 56:263-286.
51. Gradman T.J., Laws A., Thompson L.W., Reaven G.M. Verbal learning and/or memory improves with glycemic control in older subjects with non-insulin-dependent diabetes. Journal of the American Geriatrics Society 1993, 41:1305-1312.
52. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia. American Journal of Psychiatry 1996, 153:321-330.
53. Green M.F. New possibilities in cognition enhancement for schizophrenia. American Journal of Psychiatry 2009, 4:5.
54. Green M.F., Kern R.S., Braff D.L., Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the " right stuff" ?. Schizophrenia Bulletin 2000, 26:119-136.
55. Greenwood T.A., Braff D.L., Cadenhead K.S., Calkins M.E., Dobie D.J., Freedman R., et al. The consortium on the genetics of Schizophrenia (COGS): Preliminary heritability analyses of endophenotypic measures for schizophrenia. Archives of General Psychiatry 2007, 64:1242-1250.
56. Gunnell D., Rasmussen F., Fouskakis D., Tynelius P., Harrison G. Patterns of fetal and childhood growth and the development of psychosis in young males: A cohort study. American Journal of Epidemiology 2003, 158:291-300.
57. Gur R.E., Calkins M.E., Gur R.C., Horan W.P., Neuchterlein K.H., Seidman L.J., et al. The consortium on the genetics of schizophrenia (COGS): Neurocognitive endophenotypes. Schizophrenia Bulletin 2007, 33:49-68.
58. Gur R.E., Nimgaonkar V.L., Almasy L., Calkins M.E., Ragland J.D., Pogue-Geile M.F., et al. Neurocognitive endophenotypes in a multiplex multidimensional family study of schizophrenia. American Journal of Psychiatry 2007, 164:813-819.
59. Hall J., Whalley L.J., Marwick K., McKirdy J., Sussmann J., Romaniuk L., et al. Hippocampal function in schizophrenia and bipolar disorder. Psychological Medicine 2010, 40:761-770.
60. Harris E., Barraclough B. Excess mortality of mental disorder. British Journal of Psychiatry 1998, 173:11-53.
61. Harrison P.J. The hippocampus in schizophrenia: A review of the neuropathological evidence and its pathophysiological implications. Psychopharmacology 2004, 174:151-162.
62. Harvey P.D. Pharmacological cognitive enhancement in schizophrenia. Neuropsychological Review 2009, 19:324-335.
63. Heckers S., Rauch S.L., Goff D., Savage C.R., Schacter D.L., Fischman A.J., et al. Impaired recruitment of the hippocampus during conscious recollection in schizophrenia. Nature Neuroscience 1998, 1:318-323.
64. Heinrichs R.W. The primacy of cognition in schizophrenia. American Psychologist 2005, 60:229-242.
65. Heinrichs R.W., Zakzanis K.K. Neurocognitive deficit in schizophrenia: A quantitative review of the evidence. Neuropsychology 1998, 12:426-445.
66. Hennah W., Thompson P., Peltonen L., Porteous D. Genes and schizophrenia: Beyond schizophrenia: The role of DISC1 in major mental illness. Schizophrenia Bulletin 2006, 32:409-416.
67. Hill S.K., Beers S.R., Kmiec J.A., Keshavan M.S., Sweeney J.A. Impairment of verbal memory and learning in antipsychotic-naive patients with first-episode schizophrenia. Schizophrenia Research 2004, 68:127-136.
68. Hoang L.T., Kesner R.P. Dorsal hippocampus, CA3, and CA1 lesions disrupt temporal sequence completion. Behavioral Neuroscience 2008, 122:9-15.
69. Holt R.I.G., Pevelert R.C., Byrne C.D. Schizophrenia, the metabolic syndrome and diabetes. Diabetic Medicine 2004, 21:515-523.
70. Husted J.A., Lim S., Chow E.W., Greenwood C., Bassett A.S. Heritability of neurocognitive traits in familial schizophrenia. American Journal of Medical Genetics (Neuropsychiatric Genetics) 2009, 150B:845-853.
71. Jabben N., Arts B., van Os J., Krabbendam L. Neurocognitive functioning as intermediary phenotype and predictor of psychosocial functioning across the psychosis continuum: Studies in schizophrenia and bipolar disorder. Journal of Clinical Psychiatry 2010, 71:764-774.
72. Joyce E. Origins of cognitive dysfunction in schizophrenia: Clues from age at onset. British Journal of Psychiatry 2005, 86:93-95.
73. Keefe R.S.E., Bilder R.M., Davis S.M., Harvey P.D., Palmer B.W., Gold J.M., et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Archives of General Psychiatry 2007, 64:633-647.
74. Keefe R.S.E., Seidman L.J., Christensen B.K., Hamer R.M., Sharma T., Sitskoorn M.M., et al. Long-term neurocognitive effects of olanzepine or low-dose haloperidol in first-episode psychosis. Biological Psychiatry 2006, 59:97-105.
75. Kellendonk C., Simpson E.H., Kandel E.R. Modeling mouse endophenotypes of schizophrenia in mice. Trends in Neurosciences 2009, 32:347-358.
76. Kern R.S., Nuechterlein J.M., Green M.F., Baade L.E., Fenton W.S., Gold J.M., et al. The MATRICS consensus cognitive battery, part 2: Co-norming and standardization. American Journal of Psychiatry 2008, 165:214-220.
77. Kirkpatrick B., Miller B.J., Garcia-Rizo C., Fernandez-Egea E., Bernardo M. Is abnormal glucose tolerance in antipsychotic-naive patients with nonaffective psychosis confounded by poor health habits?. Schizophrenia Bulletin 2010, (Epub ahead of print).
78. Kolomeets N.S., Orlovskaya D.D., Rachmanova V., Uranova N.A. Ultrastructural alterations in hippocampal mossy fiber synapses in schizophrenia: A post-mortem morphometric study. Synapse 2005, 57:47-55.
79. Kolomeets N.S., Orlovskaya D.D., Uranova N.A. Decreased numerical density of CA3 hippocampal mossy fiber synapses in schizophrenia. Synapse 2007, 61:615-621.
80. Koolschijn P.C.M.P., van Haren N.E.M., Cahn W., Schnack H.G., Janssen J., Klumpers F., et al. Hippocampal volume change in schizophrenia. Journal of Clinical Psychiatry 2010, 71:737-744.
81. Kopf S.R., Buchholzer M.L., Hilgert M., Loffelholz K., Klein J. Glucose plus choline improve passive avoidance behavior and increase hippocampal acetylcholine release in mice. Neuroscience 2001, 103:365-371.
82. Koponen H., Vuononvirta J., Maki P., Miettunen J., Moilanen I., Taanila A., et al. No difference in insulin resistance and lipid levels between controls and adolescent subjects who later develop psychosis. Schizophrenia Research 2008, 104:31-35.
83. Korol D.L., Gold P.E. Glucose, memory, and aging. American Journal of Clinical Nutrition 1998, 67:764S-771S.
84. Kraepelin, E. (1919/1971). Dementia praecox and paraphrenia ((facsimile of 1919 edition) ed.). Huntington, New York: Robert Krieger.
85. Kravariti E., Morris R.G., Rabe-Hesketh S., Murray R.M., Frangou S. The Maudsley early onset schizophrenia study: Cognitive function in adolescents with recent onset schizophrenia. Schizophrenia Research 2003, 61:137-148.
86. Kremen W.S., Hoff A.L. Neurocognitive deficits in the biological relatives of individuals with schizophrenia. Early clinical intervention and prevention with schizophrenia 2004, 133-158. Humana Press, Totowa, New Jersey. W.S. Stone, S.V. Faraone, M.T. Tsuang (Eds.).
87. Kvajo M., McKellar H., Arguello P.A., Drew L.J., Moore H., MacDermott A.B., et al. A mutation in mouse Disc1 that models a schizophrenia risk allele leads to specific alterations in neuronal architecture and cognition. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:7076-7081.
88. Labrie V., Lipina T., Roder J.C. Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia. Psychopharmacology 2008, 200:217-230.
89. Law A.J., Deakin J.F. Asymmetrical reductions of hippocampal glutamate receptor nRNA in the psychoses. Neuroreport 2001, 12:2971-2974.
90. Leavitt V.M., Goldberg T.E. Episodic memory in schizophrenia. Neuropsychological Review 2009, 19:312-323.
91. Lee I., Kesner R.P. Encoding versus retrieval of spatial memory: Double dissociation between the dentate gyrus and the perforant path inpus into CA3 in the dorsal hippocampus. Hippocampus 2004, 14:66-76.
92. Leucht S., Burkard T., Henderson J., Maj M., Sartorius N. Physical Illness and schizophrenia: A review of the literature. Acta Pscyhiatrica Scandinavica 2007, 116:317-333.
93. Lewandowski K.E., Cohen B.M., Ongur D. Evolution of neuropsychological dysfunction during the course of schizophrenia and bipolar disorder. Psychological Medicine 2011, 41:225-241.
94. Lin P.I., Shuldiner A.R. Rethinking the genetic basis for comorbidity of schizophrenia and type 2 diabetes. Schizophrenia Research 2010, 123:234-243.
95. McKee A.G., Loscher J.S., O'Sullivan N.C., Chadderton N., Palfi A., Batti L., et al. AAV-mediated chronic over-expression of SNAP-25 in adult rat dorsal hippocampus impairs memory-associated synaptic plasticity. Journal of Neurochemistry 2010, 112:991-1004.
96. McNay E.C., Fries T.M., Gold P.E. Decreases in rat extracellular hippocampal glucose concentration associated with cognitive demand in a spatial task. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:2881-2885.
97. McNay E.C., Gold P.E. Extracellular glucose concentrations in the rat hippocampus measured byzero-net-flux: Effects of microdialysis flow rate, strain and age. Journal of Neurochemistry 1999, 72:785-790.
98. McNay E.C., McCarty R.C., Gold P.E. Fluctuations in brain glucose concentration during behavioral testing: Dissociations between brain areas and between brain and blood. Neurobiology of Learning and Memory 2001, 75:325-337.
99. Meneilly G.S., Cheung E., Tessier D., Yakura C., Tuokko H. The effect of improved glycemic control on cognitive functions in the elderly patient with diabetes. Journal of Gerontology 1993, M117:M121.
100. Mesholam-Gately R., Giuliano A.J., Faraone S.V., Goff K.P., Seidman L.J. Neurocognition in first-episode schizophrenia: A meta-analytic review. Neuropsychology 2009, 23:315-336.
101. Mukherjee S., Schnur D.B., Reddy R. Family history of type 2 diabetes in schizophrenic patients. Lancet 1989, 1:495.
102. Nakata K., Lipska B.K., Hyde T.M., Ye T., Newburn E.N., Morita Y., et al. DISC1 splice variants are upregulated in schizophrenia and associated with risk ploymorphisms. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:15873-15878.
103. Neeltje E.M.V.H., van Haren E.M., Pol H.E.H., Schnack H.G., Cahn W., Brans R., et al. Progressive brain volume loss in schizophrenia over the course of the illness: Evidence of maturational abnormalities in early adulthood. Biological Psychiatry 2008, 63:106-113.
104. Neuchterlein K.H., Green M.F., Kern R.S., Baade L.E., Barch D.M., Cohen J.D., et al. The MATRICS consensus cognitive battery, part 1: Test selection, reliability, and validity. American Journal of Psychiatry 2008, 165:203-213.
105. Newcomer J.W. Metabolic syndrome and mental illness. American Journal of Managed Care 2007, 13(Suppl. 7):S170-S177.
106. Newcomer J.W., Craft S., Fucetola R., Moldin S.O., Selke G., Paras L., et al. Glucose-induced increase in memory performance in patients with schizophrenia. Schizophrenia Bulletin 1999, 25:321-335.
107. Newcomer J.W., Haupt D.W., Fucetola R., Melson A.K., Schweiger J.A., Cooper B.P., et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Archives of General Psychiatry 2002, 59:337-345.
108. Nieto R.G., Castellanos F.X. A meta-analysis of neuropsychological functioning in patients with early onset schizophrenia and pediatric bipolar disorder. Journal of Child and Adolescent Psychology 2011, 40:266-280.
109. Nuechterlein K.H., Barch D.M., Gold J.M., Goldberg T.E., Green M.F., Heaton R.K. Identification of separable cognitive factors in schizophrenia. Schizophrenia Research 2004, 72:29-39.
110. Ongur D., Cullen T.J., Wolf D.H., Rohan M., Barreira P., Zalesak M., et al. The neural basis of relational memory deficits in schizophrenia. Archives of General Psychiatry 2006, 63:356-365.
111. O'Tuathaigh C.M.P., Babovic D., O'Sullivan G.J., Clifford J.J., Tighe O., Croke D.T., et al. Phenotypic characterization of spatial cognition and social behavior in mice with 'knockout' of the schizophrenia risk gene neuregulin 1. Neuroscience 2007, 147:18-27.
112. Owens S.F., Picchioni M.M., Rijsdijk F.V., Stahl D., Vassos E., Rodger A.K., et al. Genetic overlap between episodic memory deficits and schizophrenia: Results from the Maudsely twin study. Psychological Medicine 2011, 41:521-532.
113. Papaleo F., Crawley J.N., Song J., Lipska B.K., Pickel J., Weinberger D.R., et al. Genetic dissection of the role of catechol-O-methyltransferase in cognition and stress reactivity in mice. Journal of Neuroscience 2008, 28:8709-8723.
114. Paul B.M., Elvevag B., Bokat C.E., Weinberger D.R., Goldberg R. Levels of processing effects on recognition memory in patients with schizophrenia. Schizophrenia Research 2005, 74:101-110.
115. Ragland J.D., Laird A.R., Ranganath C., Blumenfeld R.S., Gonzales S.M., Glahn D.C. Prefrontal activation deficits during episodic memory in schizophrenia. American Journal of Psychiatry 2009, 166:863-874.
116. Ragozzino M.E., Pal S.N., Unik K., Stefani M.R., Gold P.E. Modulation of hippocampal acetylcholine release and spontaneous alternation scores by intrahippocampal glucose injections. Journal of Neuroscience 1998, 18:1595-1601.
117. Ragozzino M.E., Unick K.E., Gold P.E. Hippocampal acetylcholine release during memory testing in rats: Augmentation by glucose. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:4693-4698.
118. Ranganath C., Minzenberg M.J., Ragland J.D. The cognitive neuroscience of memory function and dysfunction in schizophrenia. Biological Psychiatry 2008, 64:18-25.
119. Reaven G. Role of insulin resistance in human disease. Diabetologia 1988, 30:1595-1607.
120. Reichenberg A., Harvey P.D., Bowie C.R., Mojtabai R., Rabinowitz J., Heaton R.K., et al. Neuropsychological function and dysfunction in schizophrenia and psychotic affective disorders. Schizophrenia Bulletin 2009, 35:1022-1029.
121. Reif A., Schmitt A., Fritzen S., Lesch K.P. Neurogenesis and schizophrenia: Dividing neurons in a divided mind?. European Archives of Psychiatry and Clinical Neuroscience 2007, 257:290-299.
122. Rimol L.M., Hartberg C.B., Nesvag R., Fennema-Notestine C., Hagler D.J.J., Pung C.J., et al. Cortical thickness and subcortical volumes in schizophrenia and bipolar disorder. Biological Psychiatry 2010, 68:41-50.
123. Roofeh D., Cottone J., Burdick K.E., Lencz T., Gyato K., Cervellione K.L., et al. Deficits in memory strategy use are related to verbal memory impairments in adolescents with schizophrenia-spectrum disorders. Schizophrenia Research 2006, 85:201-212.
124. Ryan M.C.M., Collins P., Thakore J.H. Impaired fasting glucose tolerance in first-episode, drug naive patients with schizophrenia. American Journal of Psychiatry 2003, 160:284-289.
125. Ryan C.M., Freed M.I., Rood J.A., Cobitz A.R., Waterhouse B.R., Strachan M.W. Improving metabolic control leasd to better working memory in adults with type 2 diabetes. Diabetes Care 2006, 29:345-351.
126. Saddichha S., Manjunatha N., Ameen S., Aktar S. Metabolic syndrome in first episode schizophrenia - A randomized double-blind controlled, short-term prospective study. Schizophrenia Research 2008, 101:266-272.
127. Sawada K., Barr A.M., Nakamura M., Arima K., Young C.E., Dwork A.J., et al. Hippocampal complexin proteins and cognitive dysfunction in schizophrenia. Archives of General Psychiatry 2005, 62:263-272.
128. Seidman L.J., Cassens G.P., Kremen W.S., Pepple J.R. Neuropsychology of schizophrenia. Clinical syndromes in adult neuropsychology: The practitioner's handbook 1992, 381-449. Elsevier Science Publishers B.V. R.F. White (Ed.).
129. Seidman L.J., Faraone S.V., Goldstein J.M., Kremen W.S., Horton N.J., Makris N., et al. Left hippocampal volume as a vulnerability indicator for schizophrenia: A magnetic resonance imaging morphometric study of nonpsychotic first-degree relatives. Archives of General Psychiatry 2002, 59:839-849.
130. Seidman L.J., Giuliano A.J., Smith C.W., Stone W.S., Glatt S.J., Meyer E., et al. Neuropsychological functioning in adolescents and young adults at genetic risk for schizophrenia and affective psychoses: Results from the Harvard and Hillside adolescent high risk studies. Schizophrenia Bulletin 2006, 35:507-524.
131. Seidman L.J., Kremen W.S., Koren D., Faraone S.V., Goldstein J.M., Tsuang M.T. A comparative profile analysis of neuropsychological functioning in patients with schizophrenia and bipolar psychoses. Schizophrenia Research 2002, 53:31-44.
132. Seidman L.J., Pantelis C., Keshavan M.S., Faraone S.V., Goldstein J.M., Horton N.J., et al. A review and a new report of medial temporal lobe dysfunction as a vulnerability indicator for schizophrenia: A MRI morphometric family study of the parahippocampal gyrus. Schizophrenia Bulletin 2003, 29:803-808.
133. Seidman L.J., Stone W.S., Jones R., Harrison R.H., Mirsky A.F. Cognitive effects of schizophrenia and temporal lobe epilepsy on memory. Journal of International Neuropsychology Society 1998, 4:342-352.
134. Smith M.A., Riby L.M., van Eekelen J.A.M., Foster J.K. Glucose enhancement of human memory: A comprehensive research review of the glucose memory facilitation effect. Neuroscience and Biobehavioral Reviews 2011, 35:770-783.
135. Spelman L.M., Walsh P.I., Sharifi N., Collins P., Thakore J.H. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabetic Medicine 2007, 24:481-485.
136. Steen R.G., Mull C., McClure R., Hamer R.M., Lieberman J.A. Brain volume in first-episode schizophrenia: Systematic review and meta-analysis of MRI studies. British Journal of Psychiatry 2006, 188:510-518.
137. Stefanis N., Frangou S., Yakeley J., Sharma T., O'Connell P., Morgan K., et al. Hippocampal volume reduction in schizophrenia: Effects of genetic risk and pregnancy and birth complicaitons. Biological Psychiatry 1999, 46:697-702.
138. Stone, W. S., & Keshavan, M. S. (in press). Medical co-morbidity in schizophrenia. In B. Marcopulos, & A. J. Giuliano (Eds.), The Neuropsychology of Schizophrenia.
139. Stone, W. S., Giuliano, A. J., Tsuang, M. T., Braff, D. L., Cadenhead, K. S., Calkins, M. E., et al. (2011). Group and site differences on the California Verbal Learning Test in persons with schizophrenia and their first-degree relatives: Findings from the Consortium on the Genetics of Schizophrenia (COGS). Schizophrenia Research. [Epub ahead of print].
140. Stone, W. S., Hsi, X., Tan, L., Zhu, S., Li, L., Giuliano, A. J., et al. (submitted for publication). Neurocognitive and clinical dysfunction in adult Chinese, nonpsychotic relatives of patients with schizophrenia: Findings from the Changsha study and evidence for schizotaxia.
141. Stone W.S., Faraone S.V., Seidman L.J., Green A.I., Wojcik J.D., Tsuang M.T. Concurrent validation of schizotaxia: A pilot study. Biological Psychiatry 2001, 50:434-440.
142. Stone W.S., Faraone S.V., Su J., Tarbox S.I., Van Eerdewegh P., Tsuang M.T. Evidence for linkage between regulatory enzymes in glycolysis and schizophrenia in a multiplex sample. American Journal of Medical Genetics (Neuropsychiatric Genetics) 2004, 127B:5-10.
143. Stone W.S., Glatt S.J., Faraone S.V. The biology of schizotaxia. Early clinical intervention and prevention of schizophrenia 2004, 339-353. Humana Press, Totowa, New Jersey. W.S. Stone, S.V. Faraone, M.T. Tsuang (Eds.).
144. Stone W.S., Roe A.H., Tsuang M.T. Overlapping of the spectra: Physical comorbidity between schizophrenia and affective disorders. The overlap of affective and schizophrenic spectra 2007, 207-223. Cambridge University Press, Cambridge. A. Marneros, A.H. Akiskal (Eds.).
145. Stone W.S., Seidman L.J. Towards a model of memory enhancement in schizophrenia: Glucose administration and hippocampal function. Schizophrenia Bulletin 2008, 34:93-108.
146. Stone W.S., Seidman L.J., Wojcik J.D., Green A.I. Glucose effects on cognition in schizophrenia. Schizophrenia Research 2003, 62:93-103.
147. Stone W.S., Thermenos H.W., Tarbox S.I., Poldrack R.A., Seidman L.J. Medial prefrontal and temporal lobe activation and memory following glucose ingestion: A pilot fMRI study. Neurobiology of Learning and Memory 2005, 83:54-64.
148. Stone W.S., Wenk G.L., Olton D.S., Gold P.E. Poor blood glucose regulation predicts sleep and memory deficits in normal aged rats. Journal of Gerontology: Biological sciences 1990, 45:B169-173.
149. Strasser H.C., Lilyestrom J., Ashby E.R., Honeycutt N.A., Schretlen D.J., Pulver A.E., et al. Hippocampal and ventricular volumes in psychotic and nonpsychotic bipolar patients compared with schizophrneia patients and community control subjects: A pilot study. Biological Psychiatry 2005, 57:633-639.
150. Talbot K., Eidem W.L., Tinsley C.L., Benson M.A., Thompson E.W., Smith R.J., et al. Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. Journal of Clinical Investigations 2004, 113:1353-1363.
151. Tamminga C.A., Stan A.D., Wagner A.D. The hippocampal formation in schizophrenia. American Journal of Psychiatry 2010, 167:1178-1193.
152. Thompson P.M., Egbufoama S., Vawter M.P. SNAP-25 reduction in the hippocampus of patients with schizophrenia. Biological Psychiatry 2003, 27:411-417.
153. Thornton A.E., Van Snellenberg J.X., Sepehry A.A., Honer W.G. The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: A quantitative review. Journal of Psychopharmacology 2006, 20:335-346.
154. Tsuang M.T., Stone W.S., Auster T.L. Prevention of schizophrenia. Expert Review of Neurotherapeutics 2010, 10:1165-1174.
155. Tsuang M.T., Stone W.S., Seidman L.J., Faraone S.V., Zimmet S., Wojcik J., et al. Treatment of nonpsychotic relatives of patients with schizophrenia: Four case studies. Biological Psychiatry 1999, 41:1412-1418.
156. Tsuang M.T., Stone W.S., Tarbox S.I., Faraone S.V. Treatment of nonpsychotic relatives of patients with schizophrenia: Six case studies. American Journal of Medical Genetics (Neuropsychiatric Genetics) 2002, 114:943-948.
157. Turetsky B.T., Moberg P.J., Mozley L.H., Moelter S.T., Agrin R.N., Gur R.C., et al. Memory-delineated subtypes of schizophrenia: Relationship to clinical, neuroanatomical, and neurophysiological measures. Neuropsychology 2002, 16:481-490.
158. Tuulio-Henriksson, A., Perala, J., Saarni, S. I., Isometsa, E., Koskinen, S., Lonnqvist, J., et al. (2011). Cognitive functioning in severe psychiatric disorders: A general population study. European Archives of Psychiatry and Clinical Neuroscience. [Epub ahead of print].
159. Tuulio-Henriksson A., Partonen T., Suvisaari J., Haukka J., Lonnqvist J. Age of onset and cognitive functioning in schizophrenia. British Journal of Psychiatry 2004, 185:215-219.
160. Vawter M.P., Howard A.L., Hyde T.M., Kleinman J.E., Freed W.J. Alterations of hippocampal secreted N-CAM in bipolar disorder and synaptophysin in schizophrenia. Molecular Psychiatry 1999, 4:467-475.
161. Venkatasubramanian G., Chittiprol S., Neelakantachar N., Naveen M.N., thirthall J., Gangadhar B.N., et al. Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia. American Journal of Psychiatry 2007, 164:1557-1560.
162. Verma S.K., Subramaniam M., Liew A., Poon L.Y. Metabolic risk factors in drug-naive patients with first-episode psychosis. Journal of Clinical Psychiatry 2009, 70:997-1000.
163. von Hausswolff-Juhlin Y., Bjartveit M., Lindstrom E., Jones P. Schizophrenia and physical health problems. Acta Pscyhiatrica Scandinavica 2009, 119(supplement 438):15-21.
164. Vrajova M., Stastny F., Horacek J., Lochman J., Sery O., Pekova S., et al. Expression of the hippocampal NMDA receptor GluN1 subunit and its splicing isoforms in schizophrenia: Postmortem study. Neurochemical Research 2010, 35:994-1002.
165. Wang Q., Vassos E., Deng W., Ma X., Hu X., Murray R.M., et al. Factor structures of the neurocognitive assessments and familial analysis in first-episode schizophrenia patients, their relatives and controls. Australian and New Zealand Journal of Psychiatry 2010, 44:109-119.
166. Weinberger D.R. Cell biology of the hippocampal formation in schizophrenia. Biological Psychiatry 1999, 45:395-402.
167. Wheeler M.A., Stuss D.T., Tulving E. Frontal lobe damage produces episodic memory impairment. Journal of the International Neuropsychological Society 1995, 1:525-536.
168. Willi R., Weinmann O., Winter C., Klein J., Sohr R., Schnell L., et al. Constitutive genetic deletion of the growth regulator Nogo-A induces schizophrenia-related endophenotypes. Journal of Neuroscience 2010, 30:556-567.
169. Woodberry K.A., Giuliano A.J., Seidman L.J. Premorbid IQ in schizophrenia: A meta-analytic review. American Journal of Psychiatry 2008, 165:579-587.
170. Wright I.C., Rabe-Hesketh S., Woodruff P.W.R., David A.S., Murray R.M., Bullmore E.T. Meta-analysis of regional brain volumes in schizophrenia. American Journal of Psychiatry 2000, 157:16-25.
171. Zhou H., Lu W., Shi Y., Bai F., Chang J., Yuan Y., et al. Impairments in cognition and resting-state connectivity of the hippocampus in elderly subjects with type 2 diabetes. Neuroscience Letters 2010, 473:5-10.